Background: Current international clinical practice guidelines do not adequately
Introduction
Venous thromboembolism (VTE) is a leading cause of preventable mortality in Australia. In 2008, there were 14 716 reported cases nationally, costing the medical system an estimated $1.72 billion as well as creating a significant economic burden through loss to the workforce. 1 Despite the availability of multiple management guidelines, there are still significant areas of uncertainty in management. 2 This is largely because of the variable prognoses of individuals with VTE and gaps in the evidence base for several important clinical scenarios. In particular, significant doubt remains regarding the optimal treatment of intermediate-risk pulmonary embolism (PE).
The major institutions to publish guidelines on the management of VTE are the National Institute for Health and Care Excellence (NICE), the European Society of Cardiology (ESC) and the American College of Chest Physicians (ACCP), who have most recently published guidelines in 2012, 2014 and 2016 respectively. [3] [4] [5] These guidelines are extensive; however, there is variation in their coverage and recommendations in part because of recent changes in the evidence base. The lack of a comprehensive Australian guideline creates significant uncertainty for treating clinicians, leading to discrepancies in national standards of practice. Variation in practice has been observed in prior studies, although none of the studies addresses all areas of management, and there is limited information regarding Australian practice.
haematologists and respiratory physicians are consistent with currently available international guidelines. The outcomes of this study will aid the development of national clinical guidelines for the investigation and management of VTE. In addition, by identifying gaps in knowledge, the study highlights important areas for training and education.
Methods

Study design and ethics
We conducted a cross-sectional survey of haematologists and respiratory physicians currently working within Australia (Appendix S1). Both consultants and registrars/trainees were eligible to participate. The study was approved by the Melbourne Health Human Research Ethics Committee (Project number QA2015182).
Survey development
A draft survey was developed after an extensive literature review and review of current clinical practice guidelines. The draft survey was reviewed by 10 physicians (respiratory physicians, general physicians and haematologists) at the Royal Melbourne Hospital and Peter McCullum Cancer Centre who provided expert advice on question content and survey design. An online version of the survey was developed using Survey Monkey (www.surveymonkey.com) and was accessible through a web link. It consisted of 53 questions and took 10 min to complete.
Survey procedure
An email containing the link to the survey was sent to members of The Australasian Society of Thrombosis and Haemostasis, The Haematology Society of Australia and New Zealand (HSANZ) and The Thoracic Society of Australia and New Zealand (TSANZ). After an initial poor response rate, reminder emails were sent on at least one further occasion. Surveys were also distributed at TSANZ and HSANZ scientific meetings.
Statistical analysis
Statistical analysis was conducted using STATA IC 14.1 (StataCorp, College Station, TX, USA). Denominators for percentage calculations were adjusted to account for missing data. Chi-squared analysis was used to identify differences in survey responses between haematologists and respiratory physicians. Multivariate logistic regression was used to determine which demographicor physician-specific factors were related to physician responses. All relevant clinical and demographic factors for which data were collected were included in the analysis, including specialty, gender, years of clinical experience, metropolitan or regional practice, private hospital workplace and reported use of guidelines. P < 0.05 was considered statistically significant.
Results
Participation and demographics
Of an estimated 505 haematologists and 630 respiratory physicians registered in Australia in December 2015, 12 71 and 110, respectively, responded to the survey. Respondents who did not complete the survey beyond the demographic section were excluded, providing a response rate of 13% for haematologists and 16% for respiratory physicians. This is a conservative estimate based on the number of doctors registered with the Australian Health Practitioners Regulation Agency in 2016 rather than the number who are members of the societies who distributed the survey.
A total of 66% percent of respondents was 31-50-years old; the median number of years spent working in their speciality was 9 (interquartile range (IQR) (4, 19) ), and over 84% worked in teaching hospitals and in the acute care setting ( Table 1) . The responses to survey questions are summarised in the following text, and Table 2 includes a breakdown by specialist type for all responses, which differed significantly between respiratory physicians and haematologists.
Multivariate logistic regression was used to identify physician-specific factors associated with specific management practices. All statistically significant results are presented in Table 3 .
Knowledge and use of guidelines
Doctors were more familiar with the Australian Therapeutic Guidelines (ATG) 13 and ACCP's 2012 and 2016 5 guidelines (47, 44 and 54% respectively) than the ESC 4 and NICE 3 guidelines (21% and 27% respectively). A total of 5% of doctors was not familiar with any of these guidelines.
A total of 77% of doctors agreed that they usually base clinical decisions on one or more of these guidelines.
Initial assessment of PE
The vast majority of doctors (96%) were familiar with the Wells score for assessing the probability of having a Australian VTE management survey VTE; however, 38% said they would rarely or never calculate and record it. A total of 61% of doctors was familiar with the Pulmonary Embolism Severity Index (PESI). Only 25% regularly use the PESI/simplified PESI (sPESI), whereas most doctors regularly use cardiac biomarkers (60%) and/or imaging a (74%).
Managing low-risk PE
A total of 56% of respondents usually admit a patient with low-risk PE for 1-2 days (where social circumstances and comorbidities permit early discharge). Only 4% usually admit for 3-5 days, and 40% would treat at home or discharge within 24 h.
A total of 60% of doctors surveyed would recommend anticoagulation for a patient without cancer or a deep venous thrombosis (DVT) who has an incidental asymptomatic single sub-segmental PE (SSPE) found on computed tomography pulmonary angiogram (CTPA) or ventilation perfusion (VQ) scan.
Managing high-risk PE
The majority of doctors surveyed would recommend thrombolysis for patients with high-risk PE without contraindications to thrombolysis (68%). However, 18% indicated they would rarely or never recommend thrombolysis, and 14% indicated they would only recommend thrombolysis sometimes. Using thrombolysis never or rarely was almost four times more likely amongst haematologists, six times more likely amongst doctors in private hospitals and showed a slight association with increasing years of clinical experience (Table 3) .
Managing intermediate-risk PE
Recommendations for thrombolysis
The majority of doctors (84%) do not recommend the use of thrombolysis for patients with intermediate-risk PE in those without contraindication to thrombolysis. More doctors would frequently or always recommend thrombolysis for patients with elevated troponin and right ventricular dysfunction (RVD) on echocardiography (16%) than for patients with elevated troponin and RVD dysfunction on CTPA (7%). A total of 6% of doctors said they would sometimes recommend thrombolysis for patients with elevated troponin and no evidence of RVD on CTPA or echocardiography (Fig. 1) .
A total of 90% of respondents reported discussing the risks and benefits of thrombolysis with their patients. However, 22% of them stated that patient preferences do not influence their decision to use thrombolysis much or at all for intermediate-risk PE.
Only 8% of doctors surveyed said they had used halfdose thrombolysis in this patient group.
Recommendations for cardiac monitoring
A total of 91% of doctors would recommend cardiac monitoring for patients with both elevated serum troponin and features of RVD on CTPA or echocardiography; 62% recommend monitoring for patients with features of RVD on CTPA or echocardiogram but without elevated troponin, while 49% recommend monitoring for patients with an elevated troponin but without features of RVD.
Screening for thrombophilia and malignancy
For patients with a first-episode unprovoked PE, 88% of doctors would frequently or always recommend patients be up-to-date with national screening tests.
b A total of 54% would recommend a thrombophilia screen; however, only 17% recommend a computed tomography (CT) chest/abdomen/pelvis or CT abdomen/pelvis to screen for occult malignancy in patients over 40 years of age.
Follow up of PE
A total of 35% of respondents routinely order a VQ scan before cessation of anticoagulation for unprovoked PE, whereas 5% would routinely order a CT; 17% routinely order either. A total of 16% of doctors routinely use echocardiogram during follow up of individuals with unprovoked PE; 51% use echocardiography during the follow up of patients who had features of RVD and/or pulmonary hypertension detected at the time of initial diagnosis, and 45% use it for those with persisting symptoms (multiple answers were possible for this question).
Choice of anticoagulant
Assuming there are no contraindications, 76% of doctors prefer to prescribe new oral anticoagulants over vitamin K antagonists for patients with PE without cancer.
Long-term management of VTE in patients without transient risk factors
Only 40% of doctors stated they would recommend aspirin for patients ceasing anticoagulation after an episode of unprovoked PE. Only 18% of doctors said they frequently or always use follow-up d-dimer tests to guide the duration of anticoagulation in unprovoked PE.
Duration of anticoagulation
A total of 41% of doctors said they would anticoagulate first-episode provoked PE for a 6-or 12-month period (Table 4) . Most doctors (83%) would also recommend anticoagulation for fixed periods of 6 or 12 months for patients with unprovoked first-episode PE. For firstepisode PE with active cancer, unprovoked secondepisode PE and first-episode PE with significant irreversible risk factors other than cancer, the majority of doctors would recommend indefinite c anticoagulation (81, 65 and 63% respectively). 
Discussion
The survey revealed considerable variability in VTE management practices across multiple areas. Some of this variation may be because of discrepancies and gaps in recommendations from the ATG, NICE, ESC and ACCP as 77% of respondents said they base management decisions on one or more of these guidelines. Table 5 describes some of the areas where recommendations are absent or vary between these publications. The ATG were excluded as they are not comprehensive. For the purpose of this discussion, we have classified areas of variability in practice into three broad categories: areas of uncertainty, over-treatment and under-treatment. A practice was only considered over-or undertreatment if results deviated from a recommendation that is consistent across the three guidelines in Table 5 . We acknowledge that more recent recommendations may be supported by better evidence.
Areas of uncertainty
Weighing patients' preferences
Patients' preferences for thrombolysis in intermediaterisk PE are important because of the nature of the risks, including debilitating stroke and intracranial haemorrhage, 14 and benefits of treatment. Surprisingly, 10% of doctors reported that they do not discuss the risks and benefits of thrombolysis with their intermediate-risk patients, and 22% of those who do said patient preferences do not influence their decision to thrombolyse 'much or at all'.
Thrombophilia and cancer screening in firstepisode unprovoked PE
The results indicate that thrombophilia screening for patients with first-episode unprovoked PE is ordered with varying frequency. This is consistent with findings from an American retrospective study which showed that thrombophilia testing is performed in an unstructured manner. 15 Guidance in this area is limited (Table 5) , and epidemiological data from the German MAISTHRO registry 16 and multination REITE registry 17, 18 did not clearly identify patient groups who will benefit from testing. It is also unclear if test results are altering management decisions.
With regards to cancer screening, 12% of doctors do not regularly recommend being up-to-date with national screening programmes, while 17% regularly order a screening CT abdomen/pelvis in over 40-year olds. The NICE guidelines recommend the consideration of a screening CT abdomen/pelvis in patients over 40 years if initial investigations for cancer are negative; 8 however, several more recent publications do not. Australian guidelines could unify the approach and may reduce unnecessary screening.
Aspirin use
The ACCP's 2016 guidelines recommend aspirin for patients ceasing anticoagulation for an unprovoked PE (Table 5) . 5 This recommendation is supported by two RCT published in 2012. 22, 23 Despite this, only 40% of respondents recommend aspirin in this instance.
Management of low-risk PE
The survey showed that 66% of doctors would anticoagulate patients with asymptomatic SSPE without concomitant DVT. These findings are consistent with those of a 2013 European survey. 8 The ACCP's 2016 guideline recommends that these patients should not receive anticoagulation (Table 5) . 5 There are no published RCT on the subject, 24 and the other guidelines do not make a recommendation.
Follow-up scans
A total of 16% of doctors routinely request echocardiograms during the follow up of individuals with unprovoked PE. Routine use is unlikely to be beneficial for identifying chronic thromboembolic pulmonary hypertension (CTEPH), 19 although two moderate-sized cohort studies indicate that follow-up echocardiography may be useful to diagnose CTEPH in a subset of patients. 20, 21 The ESC's guideline has recommendations for follow-up screening of patients at risk of CTEPH, although none of the guidelines consider follow-up imaging for other indications (Table 5) . A total of 35% of respondents order a VQ scan for routine follow up on cessation of anticoagulation after unprovoked PE. Evidence regarding the usefulness of follow-up imaging to tailor anticoagulation duration is limited. A small study from 2015 found that the risk of recurrent VTE was not associated with residual thromboembolic obstruction on CT. 16 However, VQ single photon emission CT may be useful for tailoring the duration of anticoagulation based on the resolution of perfusion defects. [25] [26] [27] Further research is required to establish the utility of ordering tests in this situation.
Areas of uncertainty in duration of anticoagulation
Anticoagulation practices were variable for unprovoked second-episode PE and first-episode PE with significant irreversible risk factors other than cancer. Discrepancies in guideline recommendations broadly reflect this (Table 5) . These results are consistent with findings from the European REITI registry, which found heterogeneous anticoagulation practices. 6 
Areas of under-treatment
The major guidelines recommend using thrombolysis for high-risk PE unless the patient has a clear contraindication (Table 5) . [3] [4] [5] 13, 28 However, the results of this survey suggest that there is a level of under-treatment of highrisk PE by some physicians, which is consistent with results from overseas studies. Analysis of the American EMPEROR registry showed that in the period 2006-2008, only 7 of 58 patients admitted with high-risk PE received thrombolysis. 9 This study also found a trend of reduced mortality in the thrombolysis group compared with those who did not receive thrombolysis, although the study was underpowered to detect a true difference. 9 A European study found similar results. No specific recommendation.
States that patients with severe symptoms or marked cardiopulmonary impairment should be monitored closely for deterioration †Until it appears the clinical risk of recurrent VTE no longer outweighs the risk of bleeding e.g. once there is no longer evidence of active cancer or there is a change in the underlying bleeding risk. ‡lupus anticoagulant, protein C or S deficiency, homozygous factor V Leiden or homozygous PTG20210A. §VTE in a first degree relative. ¶The ESC recommend close monitoring for cardiac decompensation in patients with RVD and elevated cardiac biomarkers. 4 † †Deterioration may include: increase in heart rate, drop in systolic BP, an increase in jugular venous pressure, worsening gas exchange, signs of shock, progressive right heart dysfunction on echocardiography or an increase in cardiac biomarkers. 5 CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest x-ray; DVT, deep venous thrombosis; Ex, examination; FBE, full blood examination; Hx, history; LFT, liver function tests; NOAC, new oral anticoagulants; PE, pulmonary embolism; SSPE, sub-segmental pulmonary embolism; VKA, vitamin K antagonists; VQ, ventilation perfusion scan; VTE, venous thromboembolism.
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There was also a tendency to under-treat first-episode unprovoked PE. The majority of physicians surveyed (73%) said they would recommend anticoagulation for periods of 6 or 12 months (Table 4) despite guidelines recommending indefinite anticoagulation e (Table 5) .
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Areas of over-treatment A significant proportion of doctors surveyed (41%) indicated that they would anticoagulate first-episode provoked PE for a period of 6 or 12 months despite consistent guideline recommendations for 3 months of anticoagulation (Table 5) . Results from the REITE registry study suggest that such variable anticoagulation practices may increase the risk for fatal bleeding. 6 Our survey also suggested over-treatment in the management of intermediate-risk PE, although to a lesser degree. In particular, 16% of doctors surveyed indicated that they would frequently or always recommend thrombolysis for normotensive patients with elevated cardiac biomarkers and evidence of RVD on echocardiogram ( Fig. 1) , with haematologists four times more likely than respiratory physicians to make this recommendation (Table 2) . However, guidelines recommend that thrombolysis be considered for this group of patients only if there is haemodynamic or clinical deterioration ( Table 5 ).
The Australian context
Our findings are consistent with the Care Track Australia study, which showed that the level of compliance with guidelines for VTE prevention and management requires improvement. 11 Efforts have been undertaken by the National Health and Medical Research Council to implement VTE prophylaxis strategies across Australia 29 ; however, these strategies have not included the management of acute VTE. A 2014 study of post-surgical VTE in New South Wales suggested that urgent policy action on all VTE management is required as the mortality rate of VTE had not changed over the period of 2002-2009. 30 
Limitations
The major limitation of this study was the low response rate. However, the survey respondents' demographic distribution is consistent with national data, 31, 32 and we believe the sample represents an adequate cross-section of haematologists and respiratory physicians.
Considerable effort was made to increase the response rate, including multiple reminders and attendance at scientific meetings. Although a high response rate is preferable, non-response rate is not a good indicator of the size of non-response bias alone, 33, 34 and our rate is similar to other surveys of Australian doctors. [35] [36] [37] Implications for practice and future research This survey highlighted key areas of over-treatment, under-treatment and uncertainty in VTE management. The development and implementation of a national evidence-based clinical practice guideline may reduce this variability and improve VTE management in Australia. There are many areas where clinical uncertainty exists because of gaps in the evidence base, which may be addressed by future research; however, in the interim, consensus statements may discourage an excessive reliance on tests of unclear utility and may help to facilitate the development of unified treatment pathways. This study provides data on which areas guidelines need to focus. In addition, it is likely that specific interventions will be needed to promote the uptake of guidelines and encourage behavioural change.
VTE is a common condition managed by general practitioners, emergency physicians, general physicians, specialist physicians and surgeons. It is important to engage all relevant clinicians and stakeholders for guideline development, and future surveys of VTE management should include practitioners not covered by this survey.
Future prospective cohort studies that link management practices to patient outcomes will provide data about variations in practice and outcomes. One study has been established, but larger studies, including multiple centres are needed. 38, 39 Guideline development could also facilitate the development of nationally standardised audit tools to evaluate VTE management.
Conclusion
This survey of respiratory physicians and haematologists has demonstrated significant variability in VTE management, some of which relates to areas of clinical uncertainty that are either not covered by current guidelines or for which guideline recommendations are inconsistent. There were also deviations from consistent guideline recommendations; in particular, there is evidence of over-treatment of patients with provoked PE and patients with intermediate-risk PE and under-treatment of patients with high-risk PE. The findings highlight the urgent need for the development and implementation of national guidelines for the management of VTE in Australia.
e Minimum 3 months anticoagulation followed extended anticoagulation until the clinical risk of recurrent VTE no longer outweighed the risk of bleeding.
